Marc Tessier-Lavigne
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Marc Tessier-Lavigne
Marc Tessier-Lavigne was last confirmed as Board Member at Denali Therapeutics Inc. (DNLI) in a filing dated April 17, 2025. Regeneron Pharmaceuticals, Inc. reported in an 8-K filed September 8, 2023 that Marc Tessier-Lavigne retired as director, effective September 1, 2023.
“On September 1, 2023, Marc Tessier-Lavigne, Ph.D. notified Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) of his decision to retire, effective as of that date, as a director of the Company.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
2015-01-01–2025-04-17
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.